Statistics in Medicine 1991: Vol 10 Index

21 Pages·1991·4 MB·English

STATISTICS IN MEDICINE VOL. 10, 2007-2008 (1991)
AUTHOR INDEX
Aalen, O. O., 1227 Cheuvart, B., 65 Graham, D. F., 33
Abt, K., 777 Chevret, S., 1647 Gra:.osch, P. M., 697
Ackermann-Liebrich, U., 1481 Chi, E. M., 1115 Greene, H. L., 1621
Altman, D. G., 733, 1897 Chmiel, J. S., 1993 Greenland, S., 79, 739, 1069
Andersen, P. K., 1061, 1931 Chow, S.-C., 1543 Griffin, P. D., 177
Anderson, S., 959 Chuang-Stein, C., 323, 1349 Grgnnesby, J. K., 1003
Armitage, P., 925 Clark, C. M., 505
Armstrong, J., 1993 Clark, W. B., 1089 Haber, M., 1573
Azen, S., 473, 1465 Cleary, J., 423 Halloran, M. E., 1573
Commenges, D., 1775 Hallstrom, A. P., 1621
Babiker, A. G. A. G., 1025 Cook, N., 1585 Halpern, A. C., 565
Bailey, R. C., 521 Costanza, M. C., 53 Hand, D. J., 1315
Baird, D. D., 255 Hansen, L. S., 1061
Bakketeig, L. S., 1003 D’ Agostino, R. B., 1, 27 Hashimoto, Y., 303
Barlow, W., 1465 D’Arcangues, C., 241 Hauck, W. W., 711, 959
Baron, A. E., 757 Dai, W. S., 565 Hayashi, M., 839
Bauer, P., 871 Damsgaard, M. T., 285 Heeren, T. C., 1, 27
Beal, S. L., 303 Davis, C. S., 1555, 1959 Heitjan, D. F., 1075
Becher, H., 375 Day, S. J., 33 Helfenstein, U., 1481
Becker, N. G., 1527 Desouza, C. M., 1241 Hennekens, C. H., 1585
Begaud, B., 991 Dixon, D. O., 21 Hildebrand, H., 1361
Begg, C. B., 1887 Dobson, A. J., 457 Hilden, J., 285
Bellissant, E., 989 Donner, A., 383, 1981 Hirji, K. F., 1137
Belsey, E. M., 267 Duncan, D. B., 21 Hirschberg, J. G., 1273
Benichou, J., 989, 1753 Dunnett, C. W., 939 Hirtz, D. G., 1595
Bergman, U., 565 Dunstan, F. D. J., 855, 981, Hlatky, M. A., 647
Berntsen, R. F., 405 1719 Hook, E. B., 717
Berridge, D. M., 1703 Hoover, D. R., 1993
Berry, G., 749 Easton, D. F., 1025 Hsieh, C.-C., 361
Bithell, J. F., 1745 Eberle, E., 457 Hubert, B., 1493
Bjgrnstad, J. F., 405 Eisenberg, B., 131 Hui, S. L., 505, 511, 1213
Blettner, M., 1511 Elashoff, R. M., 1137 Husebye, E., 1227
Blumberg, M. S., 637 Eliasziw, M., 1981 Huther, M. L., 1621
Boice, Jr., J. D., 1511 Ellenberg, J. H., 1595
Bongaarts, J., 161 Evans, A. T., 443 Inui, T. S., 653
Brant, L. J., 1453 Everitt, B. S., 1315
Braun-Fahrlander, C., 1481 Ezzet, F., 901 Jagger, C., 395
Brown, M. B., 329 James, S., 1123
Buring, J. E., 1585 Falissard, B., 949 Johnson, W. D., 1295
Burns, A., 423 Farrington, C. P., 1733 Jones, B., 1607
Byar, D. P., 663 Fife, D., 1427 Jones, W. R., 177
Flanders, W. D., 739 Joseph, M., 565
Campbell, M. J., 241 Ford, I., 1711
Campbell, M. K., 383 France, L. A., 1099 Karon, J. M., 1341
Carey, V., 1993 Frank, O., 161 Katz, B., 505
Carlin, J. B., 1527 Kay, R., 1099
Carlson, N., 267 Gail, M. H., 1167, 1819 Keiding, N., 733, 1061
Carothers, A. D., 141 Garner, J. B., 767 Kenward, M. G., 1607
Carson, J. L., 565 Gart, J. J., 1257 Kirby, S. P. J., 141
Chalmers, T. C., 971 George, V. T., 1295 Kitchin, R. M., 749
Chappell, R., 1945 Giesecke, J., 1313 Kline, G., 119
Chastang, C., 989 Goodwin, G. D., 53 Koch, G. G., 13
Chen, D., 565 Gordon, D., 423 Koepsell, T. D., 653
2008 AUTHOR INDEX
Krakauer, H., 521 Mufioz, A., 1993 Somer, A., 45
Kristiansen, S., 843 Musey, P. I., 255 Somes, G. W., 351
Kupper, L. L., 443 Stallard, E., 1043
Kushler, R. H., 329 Nedelman, J., 423 Stanek, III, E. J., 119
Kuulasmaa, K., 457 Nelson, K. B., 1595 Stern, R. S., 565
Niland, J., 473 Stigum, H., 1003
Lai, M.-Y., 1465 Nix, A. B. J., 855, 981 Stolley, P. D., 565
Lanes, S. F., 1181 Strom, B. L., 565
Lang, J. M., 1585 O’Brien, P. C., 9, 697 Sullivan Pepe, M., 413
Langholz, B., 473 O’Quigley, J., 1647 Sundet, J. M., 1003
Laska, E. M., 17 Odaka, N., 1993 Sutton, C. J., 395
Lasserre, V., 909 Oden, N. L., 1303
Lawrence, C. E., 423 Odom-Maryon, T., 473 Tamhane, A. C., 939
Lawrence, C. J., 831 Olschewski, M., 1915 Tan, S.-J., 1137
Le C. F.; 1267 Orav, E. J., 599 Taylor, J. M. G., 1993
Lee, K. L., 617 Ottenbacher, K. J., 1565 Theobald, C. M., 141
Lee, M. L., 433 Thompson, M. J., 1315
Lee, Y. J., 1595 Palmer, C. R., 1327 Thomsen, B. L., 733
Lehmacher, W., 891 Palmer, R. H., 599 Thornquist, M., 413
Lellouch, J., 949 Pee, D., 1167 Tierney, W. M., 541, 1213
Lesaffre, E., 1391 Peio, J., 1025 Tilson, H. H., 565
Lewis, J. A., 1099 Petri, H., 577 Tolley, E. A., 351
Liang, K.-Y., 1197 Petroni, G. R., 1405 Transfusion Study Group, 473
Lindgren, B. R., 1267 Phelps, S. J., 351 Trewin, V. F., 831
Liu, J.-P., 1375 Piper, J., 141 Troy, S. M., 1427
Liu, X., 1197 Pryor, D. B., 617 Trussell, J., 201
Logerfo, J. P., 653 Psaty, B. M., 653 Tse, S.-K., 1543
Longini, Jr., I. M., 1573 Pulium, T. W., 191 Tubert, P., 991
Longton, G., 413
Louis, T. A., 599, 811 Raghunathan, T. E., 1417 Ulm, K., 341
Lui, K.-J., 463 Rasmussen, K., 405 Umen, A. J., 1267
Lundin, F., 565 Regal, R. R., 717 Urquhart, J., 577
Lusher, J. M., 433 Richardson, S., 95, 1493
Robins, J., 79 Vermund, S. H., 1993
Rosenberg, P. S., 1167 Vernon, P., 423
Machin, D., 241 Rosner, B., 1441, 1585
Magnus, P., 1003 Rossiter, J. E., 1693 Wagner, E. H., 653
Magnusson, I., 1089 Royston, P., 221, 675, 691, Wahl, P., 653
Manton, K. G., 1043 1283 Walker, A. M., 1181
Marks, R. G., 1089 Rubin, D. B., 585 Wanner, H. U., 1481
Marshall, R. W., 1719 Ryan, L., 65 Watier, L., 1493
Matthews, J. N. S., 691 Watson, L. F., 1527
McConnaughey, D. R., 255 Safran, C., 559 Webster, K. M., 383
McCrory, S. J., 1711 Sato, T., 1037 Weinberg, C. R., 255
McDonald, C., 505, 511, 541 Scalia-Tomba, G., 1313 Weng, C.-S., 1375
McLaughlin, C. G., 1405 Schenker, N., 585 Whaley, F. S., 723
McMahon, Jr., L. F., 1405 Scherer, J., 457 Whitehead, A., 1665
Meisner, M. J., 17 Schinnar, R., 565 Whitehead, J., 901, 1665, 1703
Metzler, C. M., 961 Schmidt, L., 285 Wilcox, A. J., 255
Mickey, R. M., 53 Schulgen, G., 1915 Willey, E. S., 351
Miike, R., 711 Schumacher, M., 1915 Wing, S., 1043
Miller, M. E., 1213 Schwartzbaum, J. A., 1273 Wolfe, R. A., 1405
Mock, P. A., 749 Senn, S. J., 1361, 1679 Wright, E. A., 599
Mode, C. J., 1427 Shaw, M., 565
Modvig, J., 285 Sheiner, L. B., 303 Yang, M. C. K., 1089
Mohberg, N. R., 1349 Shih, W. J., 323 Yoshimura, I., 839
Molenberghs, G., 1391 Simon, R., 1789
Mollie, A., 95 Sinkula, M. S., 1349
Monsour, M. J., 443 Siscovick, D., 653 Zagar, A. J., 7
Moreau, T., 1755 Smith, L., 1441 Zeger, S. L., 45
Morrell, C. H., 1453 Smith, P. J., 113 Zelterman, D., 1267
Moses, L. E., 629 Snyder, E. S., 565 Zipfel, A., 807
STATISTICS IN MEDICINE, VOL. 10, 2009-2027 (1991)
SUBJECT INDEX*
Notes: Single page numbers refer to individual papers. The page ranges shown, indicate collections of papers
on particular subjects. (L) after some page numbers identifies letters.
Abortions clinical trials, 1595
risk estimation, 285 crossover trials, 1099, 1361
Absolute risk, 1025, 1745 design effect, determination, 53
Accuracy factorial analysis, 1565
assay variability estimation, 1543 multiple compurison procedures, |
diagnostic methodology, 1887 sample size estimation, 33
interlaboratory studies, 843 ANCOVA see Analysis of covariance
ACE algorithm, 697 Angina pectoris
Acquired immunodeficiency syndrome see AIDS crossover studies, 1099
Age ANOVA see Analysis of variance
cancer competing mortality trials, 65 ARIMA see Autoregressive integr. ..
cohort studies, 1043 Artefacts
community intervention studies, 53 EEG readings, 1719
hazardous exposure estimation, 79 Association
median error, 1313 contingency tables, 1555
radiation-dose risk, 1511 Asthma
AIC see Akaike information criterion crossover trials, 1115, 1361
AIDS falsification issue, 1679
cohort studies, 1993 misclassification, 1181
databases study, 559 Attributable risk, 1753, 1819
HIV transmission model, 1003 Autoregressive integrated moving average models
incubation period estimation, 1733 EEG artefacts detection, 1719
mean-squared error estimates, 1167 time series analysis, 1481, 1493
multiple imputation methods, 585 Autoregressive models, 492-495(L)
projection methods, 1527
risk, variable infectivity, 131 Bailey-Makeham model, 521
sample size estimation, 1993 Baseline measurements
stochastic processes, 1427 comparisons, 797—799(L), 1157—1159(L)
survival function, 413 crossover trials, 1361
Akaike information criterion, 1043 databases methodology, 617
Algorithms misclassifica‘*.n, 361
see also Expectation maximization sampling design, 1945
ACE, 697 Bayesian inference
ovulation estimation, 255 bioequivalence studies, 961
PulseFit, 329 biopharmaceutical research, 811
stepwise, 711 cancer cohori models, 1241
Allocation methods, 1679, 1789 cancer mortality rates, 95
Alzheimer’s disease, 1711 change-point process, 221, 1159-1160(L)
Analysis of covariance clinical trials review, 1789
clinical trials, 797-799(L), 1157-1159(L) confidence intervals, 443
crossover trials, 1361 contingency tables, 991
Analysis of variance databases methodology, 617
assay variability estimation, 1543 descriptive data analysis, 777
* Compiled by Richard Raper, Managing Editor, Indexing Specialists, 202 Church Road, Hove, East Sussex, BN3 2DJ, U.K.
2010 SUBJECT INDEX
Bayesian inference (cont.) chi-squared adjustment, 1981
dose-finding study, 1647 estimators comparison, 723
epidemiological models, bibliography, 1819 homogeneity tests, 1257
incomplete administrative lists, 113 logistic regression, 1213
interim analysis, 925 meta-analyses, 1665
multiple comparison testing, 1 multivariate probit analysis, 1391
multiple imputation methods, 585 phase II clinical trials, 1327
pooling controls, 1417 random effects model, 901
repeated events analysis, 1227 relative risk estimation, 1745
time series analysis, diseases, 1481 repeated measurement analysis, 1959
variance components study, 599 titration study, 323
Beta distribution, 989 Binomial distribution, 443, 1417
Beta-blocker heart attack trial (BHAT), 925 Binomial trials, 405, 1137
Bias Bioavailability studies, 961, 1375
age-related mortality trials, 65 Bioequivalence studies, 959, 961, 1375
AIDS estimates, 1167 Biopharmaceutical research, 811
assay variability estimation, 1543 Birth control see Contraception; Fertility
Bayesian methods, 811 Blinding
case-control studies, 653 clinical trials, 1679
clinical trials review, 1789 Blood pressure
covariate imbalance, 797—799(L), 1157—1159(L) clinical trials, benefits/risks, 1349
crossover trials, 489-491(L), 891, 1099, 1361 crossover studies, 1115
databases analyses, 511, 541, 629 error, linear models, 1197
diagnostic tests review, 1887 multivariate probit analysis, 1391
discussion, 667 regression, variability effect, 1295
drugs effects study, 577 variance components estimation, 1441
efficacy, estimating, 45 BMDP computer package, 599, 711, 1441,
epidemiological models, bibliography, 1819 1711
error, linear models, 1197 Bone marrow transplant study, 413
generalized linear models, 1069 Bonferroni significance tests, 777, 939, 1123,
hazard ratio, point estimation, 749 1711
historical control study, 839 Book reviews
HIV study, 423, 1167 Altman, D. G., Practical Statistics for Medical
interim analysis, 925 Research, 1635
kappa estimation, 1303, 1465 Andersen, B., Methodological Errors in Medical
maximum likelihood estimation, 723 Research, 803
median age calculation, 1313 Band, P. (Ed.), Occupational Cancer
meta-analyses, 971 Epidemiology, 1786
method comparison studies, 981 Bennett, J. H. (Ed), Statistical Inference and
misclassification, epidemiology, 361 Analysis: Selected Correspondence of R.
misreports, population data, 191 A., Fisher, 1326
normal reference ranges, 691 Boyle, P., Muir, C. S., Grundmann, E. (Eds),
odds ratio, bootstrap, 1273 Cancer Mapping, 1473
order statistics study, 855 Britton, M. (Ed.), Mortality and Geography:
randomized clinical trials, 1595 A Review in the Mid-1980’s England and
regression model, 637 Wales, 1473
risk adjustment methods, 1753 Brown, R. A. and Beck, J.S., Medical Statistics
sample size estimation, 151—153(L), 1993 on Microcomputers, 1783
SSPE risk estimation, 1733 Bulman, J. S. and Osborn, J. F., Statistics in
therapy evaluation, 647 Dentistry, 1475
treatments comparison, 663 Buyse, M. E., Staquet M. J., Sylvester R. J.
vaccine efficacy estimation, 1573 (Eds), Cancer Clinical Trials Methods and
variance components study, 599, 1441 Practice, 502
Bibliographies Campbell, M. J. and Machin, D., Medical
clinical trials methodology, 1789 Statistics. A Commonsense Approach, 804
epidemiology statistical models, 1819 Castillo-Chavez, C. (Ed.), Mathematical
Binary variables and Statistical Approaches to AIDS
attributable risk adjustment, 1753 Epidemiology, 1638
SUBJECT INDEX 2011
Checkoway, H., Pearce, N.E. and Crawford- Rothman, K. J. (Ed.), Causal Inference, 498
Brown D.J., Research Methods in Spilker, B. and Schoenfelder, J., Presentation of
Occupational Epidemiology, 1323 Clinical Data, 1324
Cliff, A. D. and Haggett, P., Atlas of Disease Stein, F., Anatomy of Clinical Research.
Distributions: Analytic Approaches to An Introduction to Scientific Inquiry in
Epidemiological Data, 1473 Medicine, Rehabilitation and Related Health
Cochrane A. L., Effectiveness and Efficiency. Professions, 1325
Random Reflections on Health Services, 503 Streiner, D. L., Norman, G. R., Health
Dawson-Saunders, B. and Trapp, R. G., Basic Measurement Scales. A Practical Guide To
and Clinical Biostatistics, 1636 Their Development and Use, 1478
DeAngelis, C. (Ed.), An Introduction to Clinical Wassertheil-Smoller, S., Biostatistics and
Research, 1325 Epidemiology - A Primer for Health
Diggle, P. J., Time Series, a Biostatistical Professionals, 1165
Introduction, 501 Bootstrap
Dunn, G., Design and Analysis of Reliability confidence intervals, 413
Studies: the Statistical Evaluation of epidemiological models, bibliography, 1819
Measurement Errors, 155 odds ratios order, 1273
Everitt, B. S., Statistical Methods for Medical outliers detection, 1375
Investigations, 497 repeated events analysis, 1227
Fisher R. A., Statistical Methods, Experimental resampling, epidemiological study, 341
Design and Scientific Inference, 503 variance components study, 599
Gabriel, J-P., Lefévre, C. and Picard, P, (Eds), Box-Cox transformation, 675, 697
Stochastic Processes in Epidemic Theory Box-Jenkins model, 1493
(Lecture Notes in Biomathematics Voi 86), Breast cancer
1787 absolute risk, 1025
Healy, M. J. R., Glim. An Introduction, 503 community intervention study, 53
Hill, C., Com-Nougué, C., Kramar, A., Moreau, homogeneity tests, 1257
T., O’Quigley, J., Senoussi, R., Chastang, stepwise regression analysis, 711
C., Analyse Statistique des Données de Breastfeeding
Survie, 1476 fertility regulation, 161
Hosmer, D. W. and Lemeshow, S., Applied Bronchitis
Logistic Regression, 1162 epidemiological studies, 341
Howson, C. and Urbach, P., Scientific Reasoning,
The Bayesian Approach, 1161 Cancer
Junshi, C., Campbell, C. T., Junyao, L., Peto, R., see also Breast cancer
Diet, Life-style and Mortality in China : A absolute risk, 1025
Study of the Characteristics of 65 Chinese age-related mortality adjustment, 65
Counties, 1473 attributable risk adjustment, 1753
Kahn, H. A., Sempos, C. T., Statistical Methods case-control studies, 375
in Epidemiology, 501 clinical trials review, 1789
Kirkland, D. J. (Ed.), Statistical Evaluation of diagnostic tests review, 1887
Mutagenicity Test Data, 156 endometrial, kappa’s standard error, 767
Laboratory Anim Sci. Assoc and Universities generalized linear models, 1069
Fed for Anim. Welfare, Guidelines on the hazardous exposure estimation, 79
Care of Laboratory Animals and Their Use mortality rates, EB estimates, 95
for Scientific Purposes., IV 1785 phase I clinical trials, 1647
Last J. M. (Ed.), A Dictionary of Epidemiology, phase II clinical trials, 989
502 physicians’ health study (US), 1585
Madansky, A., Prescriptions for Working quality of life analysis, 1915
Statisticians, 1637 relative risk estimation, 1745
Maxwell, S. E., Delany, H. D., Designing risk techniques, leukaemia, 1511
Experiments and Analyzing Data. A Model skin melanoma, cohort models, 1241
Comparison Perspective, 1477 survival function, 413
Miller, A. J., Subset Selection in Regression, triangular test comparisons, 989
1164 tumour growth models, 1075
Noreen, E. W., Computer Intensive Methods for Cardiac Arrhythmia Suppresion Trial, 1621
Testing Hypotheses, 499 Cardiology
Rosner, B., Fundamentals of Biostatistics, 1783 quality of life assessment, 1915
2012 SUBJECT INDEX
Cardiovascular diseases kappa coefficient, 1465
see also Heart disease ordinal models, 383
normality departure estimation, 1283 Clinical trials
response phenomenon, 1621 see also crossover trials; randomization
Carryover effects, 901 age-related adjustment, 65
categorical data analysis, 1607 Bayesian analysis, 811
crossover trials, 489-491(L), 1361 bioequivalence studies, 959, 961
dose ranging simulation study, 303 biologic efficacy, 45
CART program package, 1789 blinding, 1679
Case-control studies categorical data analysis, 1607
absolute risk, 1025 colorectal cancer, 65
cohort design, 1775 correlation anomalies, 1315
epidemiological models, bibliography, 1819 covariate inbalance, 797—799(L), 1157—1159(L)
estimation, 1037 databases comparison, 511, 541, 599, 663
homogeneity, 1257 decision analysis, 1789
hypertension, 653 descriptive data analysis, 777
nested analysis, 739 diagnostic tests, 1341, 1887
polychotomous models, 375 disease indicators, 1061
pooling controls, 1417 dose ranging simulation study, 303
relative risk, 1511 EEG readings artefacts, 1719
risk adjustment methods, 1753 endpoints, 1789
survival-based, 1775 error, 1789
Categorical data factorial designs, 1789
clinical trials, benefits/risks, 1349 falsification issues, 1679
crossover trials, 1607 fertility regulating vaccine, 177
repeated measurement analysis, 1959 futility testing, 405
survival analysis, 1703 group sequential designs, 405, 1789
Censored data haemophiliac study, 433
case-control studies, 739, 1775 hypothesis testing, 433, 777, 1679, 1789
Cox regression review, 1931 interaction interpretation, 1565
median age calculation, 1313 interim analysis, 925, 949, 1897
multiple imputation methods, 585 interpretation relevance, 1679
order statistics study, 855 journal developments, 1897
repeated events analysis, 1227 meta-analyses, 971, 1665, 1789, 1897
sample size estimation, 1993 methodology ten year review, 1789
sampling design, multiwave studies, 1945 multiple testing, 871, 939, 1123
survival analysis, 413, 1703, 1931 multiplicity problems, 1789
variance components estimation, 1441 over-the-counter drugs, 1
Centile estimates, 675, 691, 1693 parametric approach, 1665
Change-point process phase I cancer trials, 1647
fertile phase identification, 221 phase II trials, 989, 1327, 1789
registry data, 1159-1160(L) phase III trials, 1349, 1789
time series analysis, 1481 quality of life overview, 1915
Chi-squared tests repeated events analysis, 1227
binomial comparisons, 1137 repeated measurements analysis, 1959
change-point testing, 1159-1160(L) response phenomenon, 1621
nominal association model, 1555 sample size, 33, 1789, 1897
paired data adjustment, 1981 sequential designs, 1789
Children survival analysis, 1703, 1931
clinical trials, 1595 toxicity evaluation, 1089
respiratory diseases, 1481 triangular test comparisons, 901
Cholesterol ClinQuery computer package, 559
normality departure estimation, 1283 Cluster analysis
provisional diagnoses, 1341 chi-squared adjustment, 1981
regression, variability effects, 1295 community intervention studies, 53
Classification epidemiological models, bibliography, 1819
chromosome study, 141 sampling variance estiamtion, 53
databases study, 637 variance components study, 599
SUBJECT INDEX
Cohen’s kappa standard error study, 767 hazards ratio, point estimation, 749
Cohort studies journal developments, 1897
active life expectancy assessment, 1945 kappa statistic, 767, 1303
age-mortality relationship, 1043 meta-analyses, 971
ambidirectional design, 1775 multiple testing, 871, 939
cancer epidemiology, 1241 odds ratio order, 1273
case-control studies, 739 Poisson distribution, 457
contingency tables, 151—-153(L) pooling controls, 1417
epidemiological models, bibliography, 1819 population size, 717
generalized linear models, 1069 post-test probability, 443
hazardous exposure estimation, 79 provisional diagnoses, 1341
random selection design, 1775 relative risk estimation, 1745
relative risk, 1267 risk techniques, 1511, 1753
risk techniques, 1511 sample size estimation, 1993
sample size estimation, 1993 SSPE risk estimation, 1733
Comparisons stochastic processes, 1427
baseline measurements, 797—799(L), survival analysis, 413
1157-1159(L) varisnce component study, 599, 4211441
binomial trials, 1137 Confounding
case-control/cohort designs, 1775 clinical trials, 797—799(L), 1157-1159(L)
clinical trials, treatments, 1349 databases analysis, 511
counts/rates models, 1405 drug indication, 653
crossover trials, 1099 epidemiological models, bibliography, 1819
factorial ANOVA design, 1565 misclassification, 1181
hazard ratio estimators, 749 relative risk estimation, 1745
kappa calculation methods, 1465 Contingency tables
maximum likelihood estimators, 723 bias estimation, 723
methods, 981 case-control study, 1775
mortality studies, 1043 confidence intervals estimation, 717
multiple group, absolute risk, 1025 epidemiological models, bibliography, 1819
multiple testing, 891 factorial analysis, 1565
observational databases, 663 independence testing, 1555
periodontal disease progression, 1089 kappa study, 767
phase II clinical trials, 1327 power, 1321—1322(L)
repeated measurement analysis, 1959 quasi-exact test, 1137
response phenomenon, 1621 random models, 991
time series analysis, 1481 Continuation ratio model, 1703
treatments, significance tests, 939 Contraception
Compliance Africa, sub-Sahara, 161
clinical trial treatments, 1595 HIV model study, 1003
physicians’ health study (US), 1585 oral, absolute risk, 1025
Compound. sampling model, 811 probability, 221
Computer packages Contraceptives
BMDP, 119, 599, 711, 1441, 1711 failure, 201
clinical trials review, 1789 menstruation, 267
ClinQuery, 559 methodology, efficacy, 201
IMSL, 473 Poisson variability, 241
MINITAB, 675 Cook’s distance statistic, 1719
SAS, 119 Coronary heart disease see Heart disease
Computer programs Corrections to published papers, 1001, 1115, 1633
GAUSS, 1391 Correlations
PROC CATMOD, 1273 see also Geographical correlations
Confidence intervals cancer mortality rates, 95
absolute risk, 1025 chi-squared test, 1981
Bayesian methods, 811 clinical trials, 797-799(L), 1157-1159(L)
bioequivalence studies, 959, 961 contradictory, derived scales, 1315
case-control studies, 1037 counts/rates models, 1405
clinical trials, 1349, 1789 kappa estimation, ophthalmic data, 1303
2014 SUBJECT INDEX
Correlations (cont.) ; cancer case-control studies, 375
method comparison studies, 981 censored data, 1441
multivariate probit analysis, 1391 clinical research, 559
outliers, bioavailabilty studies, 1375 controlled clinical trials, 777
regression to the mean, 1295 databases methodology, 629
repeated measurement analysis, 1959 elderly hearing thresholds, 1453
significance testing, 1123 geriatric patients, 831
SPECT images, 1711 HIV study, 423, 473
tumour growth models, 1075 hormone pulses, 329
Costs migraine headache, 1197
cohort study, 1775 monitoring devices study, 351
Covariances, 473 ophthalmic grades, 1303
absolute risk, 1025 practice databases, 541
case-control studies, 1037 quality factors, 629
clinical trials, 797—799(L), 1157-1159(L) SPECT images analysis, 1711
generalized linear models, 1069 Data monitoring committees, 925, 1341
outliers, bioavailabilty studies, 1375 Databases
Covariates diagnostic methodology, 1887
databases analysis, 511 discussion, 667
human chromosome classification, 141 drugs effects bias, 577
imbalance tests, 797—799(L), 1157—1159(L) health-care, 585
misclassification, 1181 humongous, analysis, 511
survival analysis, 733, 1931 methodology, 617, 629, 637
Cox proportional hazards model observational, 663
age-related competing mortality trials, 65 practice, 541
case control studies, 739 Stevens-Johnson syndrome study, 565
crossover studies, 1099 therapy evaluation, 647
databases methodology, 617 variance components, 599
epidemiological study, 521, 1819 Death
estimator comparison, 749 cancer, age-related adjustment, 65
logistic regression validation, 1213 HIV population model study, 1003
meta-analyses, 1665 relative risk, homogeneity, 1267
monitoring devices efficacy, 351 Decision theory
post marital bereavement study, 395 bioequivalence studies, 959, 961
survival analysis, 733, 1025, 1703, 1931 clinical trials review, 1789
Crossover trials, 489-491(L) odds ratio, 1273
carryover problem, 1361 phase I cancer trials, 1647
categorical data analysis, 1607 phase II clinical trials, 1327
clinical trials review, 1789 Deming’s regression method, 981
dose ranging simulation study, 303 Demography
information recovery, 1115 HIV study, Norway, 1003
linear models, 909 Density
placebo effect, 1679 centiles-based, 1693
random effects model, 901 estimation techniques, 1745
residual effects, 891 Dental study, 1089, 1315
survival analysis, 1099 Designs, clinical trials
Cumulative sum method crossover trials, 303, 489-491(L), 891, 909,
disease monitoring, 1089 1115, 1361, 1607, 1789
fertility detection, 221 dose ranging simulation study, 303
threshold construction, 1493 factorial ANOVA design, 1565
Cusum see cumulative sum method fertility regulating vaccines, 177
Cuzick’s trend test, 799-800(L) group sequential, 405, 1789
interim analysis, 1789
Data collection medical journals review, 1897
analysis, 777 meta-analyses, 1789
antihypertension study, 323 methodology review, 1789
blood pressure, 1197 multiple comparison procedures, |
bone-marrow transplant study, 413 phase I cancer trials, 1647
SUBJECT INDEX
phase II trials, 1327, 1789 Drugs tests
randomized, 777, 797-799(L), 949, 1061, adverse reaction identificaticn, 831, 991
1157-1159(L), 1621 assay validation estimation, 1543
Diagnostic tests Bayesian analysis, 811
case-control studies, 653 bioequivalence studies, 959, 961
confidence intervals, 443 channelling bias, 577
laboratory studies, 843 clinical trials, 777, 1595
logistic regression validation, 1213 crossover trials, 1099, 1361
methodology review, 1887 epilepsy trials, 1719
monitoring, 351, 1341 factorial ANOVA design, 1565
Discriminant analysis, 383, 473 failure time analysis, 1703
Alzheimer’s disease, 1711 haemophilia study, 433
covariance matrices, 141 lidocaine intervention trial, 405
multiple group, 757 meta-analyses, 971
Disease surveillance multiple testing, 871, 939
Alzheimer’s, 1711 outliers detection, 1375
community intervention studies, 53 over-the-counter trials, 1
crossover trials, 1099 phase I cancer trials, 1647
epidemiological models, bibliography, 1819 physicians’ health study (US), 1585
indicators, survival analysis, 1061 practice databases, 541
misclassification, 361, 1181 provisional diagnoses, 1341
periodontal disease progression, 1089 response phenomenon, 1621
respiratory, time series, 1481 titration studies analysis, 323
risk adjustment methods, 1753
Salmonella, threshold construction, 1493 EEG readings see Electroencephalogram
transient condition qualifier, 413 readings
Diseases Efficacy
pooling controls, 1417 anti-hypertensive treatment, 653
stochastic processes, 1427 clinical trials, 45, 871
vaccine efficacy estimation, 1573 contraceptive methods, 201
Distribution crossover trials, 1099, 1115
AIDS, 1167 dropouts, titration studies, 323
Beta, 991 error, linear models, 1197
binomial, 443, 1137, 1159-1160(L), 1417 fertility regulating vaccine study, 177
group discriminant analysis, 757 interim analysis, 925
hazard rates, 1043 monitoring devices, 251
HIV, 1003, 1167 multiple testing, 871
IVDU length bias, 423 over-the-counter drugs tests, 1
median age error, 1313 phase II clinical trials, 1327
multi-normal, 1123 placebo, clinical trials, 777
normal, 1283, 1665, 1693 provisional diagnoses, 1341
reference ranges, 691 therapy databases, 647
sample size estimation, 1993 treatments, 405, 1349, 1595
sampling, 811, 1945 vaccine studies, 1573
SSPE incidence risk, 1733 Efficiency
Weibull, 663, 1227 case-control/cohort comparisons, 1775
DMC see Data monitoring committees homogeneity tests, 1257
Dose-response order statistics study, 855
assessment methods comparisons, 1647 phase I clinical cancer trials, 1647
biochemical reference ranges, 831 pooling controls, 1417
clinical trials review, 1789 sampling design, 1945
historical control study, 839 Elderly
model risk techniques, 151 active life expectancy assessment, 1945
simulation study, 303 hearing threshold models, 1453
titration studies analysis, 323 marital bereavement risk, 395
Doubling rules, 1321-1322(L) Electroencephalogram readings
Dropouts artefacts detection, 1719
efficacy, titration studies, 323 EM algorithm see Expectation maximization. . .
2016 SUBJECT INDEX
Endpoints journal developments, 1897
clinical trials, 1341, 1789 logistic regression validation, 1213
multinormal probabilities, 1123 median age calculation, 1313
quality of life analysis, 1915 meta-analyses, 971
Epidemiology method comparison studies, 981
AIDS, 1167, 1527, 1733, 1993 misclassification, 361
bibliography, statistical models, 1819 monitoring methodology, 1089
bioequivalence studies, 959 multiple comparison testing, 1
cancer models, 1241 multiple significance tests, 939
case-control studies, 1037, 1775 normality departure estimation, 1283
Cohen’s kappa standard error, 767 ophthalmic data, 1303
cohort studies, 1241, 1775 order statistics study, 855
decade review, 1819 phase II clinical trials, 989, 1327
diagnostic tests review, 1887 population data, misreports, 191
drugs effects bias, 577 regression, 697, 1123, 1295
generalized linear models, 1069 risk techniques, case-control study, 1511
HIV, 1003, 1167, 1427 sampling databases, 629
journal developments, 1897 significance tests, 1123
leukaemia, relative risks, 1511 tumour growth models, 1075
life lost estimation, 79 Type I, 1, 697, 925, 949, 1123, 1137
matched case-control studies, 375 vaccine efficacy estimation, 1573
Medicare surveillance, 521 Estimations
misclassification, 361, 1181 absolute risk, 1025
multiple significance tests, 939 accuracy, interlaboratory studies, 843
practice databases, 541 AIDS backcalculation, 1167
relative risk estimation, 1745 AIDS incubation period, 1733
respiratory diseases, 1481 AIDS projection methods, 1527
risk, homogeneity, 1267 assay validation variability, 1543
Salmonella surveillance, 1493 attributable risk adjustment, 1753
SSPE risk estimation, 1733 Bayesian methods, 113, 811
.tepwise regression analyses, 711 cancer mortality rates, 95
Stevens-Johnson syndrome study, 565 case-control studies, 739, 1037
threshold assessment, 341, 1493 centile curves, 1693
vaccine efficacy estimation, 1573 clinical trials review, 1789
variance components, censored data, 1441 Cohen’s kappa standard error, 767
Epilepsy, 1719 cohort studies, unseen sample, 1993
Equivalence trials, 1679 crossover trials, 1115, 1361
Error disease indicators analysis, 1061
see also Power dose-response rate, 323
absolute risk, 1025 efficacy, clinical trials, 45
assay variability estimation, 1543 elderly hearing models, 1453
autocorrelation risk, 492-495(L) empirical Bayes procedure, 95
bioequivalence studies, 959, 961 epidemiological studies, 341, 361
biopharmaceutical research, 811 error, linear models, 1197
clinical trials review, 1789 Fourier series density, 473
Cohen’s kappa, 767 hazard ratio methods, 749
counts/rates models, 1405 hazardous exposure life loss, 79
crossover trials, 891, 1361 HIV backcalculation, 1167
databases methodology, 617 HIV model study, 1003
discriminant classification functions, 141 HIV stochastic methods, 1427
EEG readings, detection, 1719 homogeneity tests, 1257
elderly hearing models, 1453 hormone pulses identification, 329
epidemiological models, bibliography, 1819 incomplete lists, 113
factorial ANOVA design, 1565 infection risk, SSPE incidence, 1733
Fisher’s exact test, 1321—1322(L) Jewell’s estimators, 151—153(L)
generalized linear models, 1197 kappa statistic, 1303, 1465
interim analysis, 925, 949 linear models, 909
interlaboratory studies, 843 maximum likelihood, 267, 723, 981